OncoMatch/Lung Cancer — Non-Small Cell (NSCLC)/HER2 (ERBB2)
Lung Cancer — Non-Small Cell (NSCLC)HER2 (ERBB2) Clinical Trials
HER2 (ERBB2) mutations — most commonly exon 20 insertions — are found in 2–4% of NSCLC. Trastuzumab deruxtecan (T-DXd) received accelerated FDA approval for HER2-mutant NSCLC in 2022. Active trials investigate additional HER2-directed agents, bispecific antibodies, and strategies targeting the spectrum of HER2 alterations including amplification and overexpression.
Top recruiting HER2 (ERBB2) Lung Cancer — Non-Small Cell (NSCLC) trials
Ranked by phase and US site count. See all 36 trials matched to your profile →
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Eli Lilly and Company
Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Boehringer Ingelheim
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Boehringer Ingelheim
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Daiichi Sankyo
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
Cancer Research UK
D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC
Guangdong Provincial People's Hospital